PhD Ping Yang MD

Publications (2)9.54 Total impact

• Article: Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors

  Sarah M. Rausch PhD, Matthew M. Clark PhD, Christi Patten PhD, Heshan Liu MS, Sara Felten BS, Yafei Li PhD, Jeff Sloan PhD, PhD Ping Yang MD, Sarah M. Rausch, Matthew M. Clark, Christi Patten, Heshan Liu, Sara Felten, Yafei Li, Jeff Sloan, Ping Yang
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND:Previous research has demonstrated that many lung cancer survivors report difficulties with symptom control and experience a poor quality of life (QOL). Although recent studies have suggested a relationship of single nucleotide polymorphisms (SNPs) in several cytokine genes with cancer susceptibility and prognosis, associations with symptom burden and QOL have not been examined. The current study was conducted to identify SNPs related to symptom burden and QOL outcomes in lung cancer survivors.METHODS:All participants were enrolled in the Mayo Clinic Lung Cancer Cohort following diagnosis of lung cancer. A total of 1149 Caucasian lung cancer survivors completed questionnaires and had genetic samples available. The main outcome measures were symptom burden as measured by the Lung Cancer Symptom Scale and health-related QOL as measured by the Short-Form General Health Survey.RESULTS:Twenty-one SNPs in cytokine genes were associated with symptom burden and QOL outcomes. Our results suggested both specificity and consistency of cytokine gene SNPs in predicting outcomes.CONCLUSIONS:These results provide support for genetic predisposition to QOL and symptom burden and may aid in identification of lung cancer survivors at high risk for symptom management and QOL difficulties. Cancer 2010. © 2010 American Cancer Society.
  Cancer 08/2010; 116(17):4103 - 4113. · 4.77 Impact Factor
• Article: Primary adenoid cystic carcinoma of the lung

  Marie-Christine Aubry MD, Michael C. Heinrich MD, PhD Julian Molina MD, Jean E. Lewis MD, PhD Ping Yang MD, MSc Stephen D. Cassivi MD, Christopher L. Corless MD, Marie‐Christine Aubry, Michael C. Heinrich, Julian Molina, Jean E. Lewis, Ping Yang, Stephen D. Cassivi, Christopher L. Corless
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND.Primary pulmonary adenoid cystic carcinomas (ACCs) are rare lung neoplasms that are challenging to completely resect and can exhibit poor survival. Adjuvant therapy is often ineffective and identification of a targeted novel therapy would be useful. The objective of the current study was to evaluate KIT expression and KIT-activating mutations.METHODS.Primary salivary gland-type tumors of the lung diagnosed between 1972 and 2002 at the Mayo Clinic were identified and the subset of primary pulmonary ACCs were reviewed. Immunohistochemical study for KIT expression and KIT gene mutations in exons 9, 11, 13, and 17 were performed on paraffin-embedded tissue.RESULTS.Forty-nine patients were diagnosed with primary pulmonary ACC. The majority of ACC cases were predominantly the cribriform type (74.4%). KIT immunoreactivity was evaluated in 34 cases and was found to be present in all but 1 case (97%). No mutations were detected in KIT gene exons 9, 11, 13, and 17 in a subset of 12 cases.CONCLUSIONS.Although KIT expression was found frequently in primary pulmonary ACC, a correlation with KIT-activating mutations was not observed. Cancer 2007. Published 2007 by the American Cancer Society
  Cancer 11/2007; 110(11):2507 - 2510. · 4.77 Impact Factor